Rowagel

Quick links to important sections

Rowagel

Method of action: Anti-Inflammatory

Treatment option: Stomatitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rowagel

Property Description
Active Ingredient Carbenoxolone Sodium
Form 2% Gel
Pharmacological Class Topical Oral Anti-Ulcer Agent
Common Use (General) Supporting healing of superficial tissue breakdown
Origin Synthetic derivative (Triterpenoid class)

Rowagel: Identity and Pharmacological Classification

Rowagel is a pharmaceutical preparation, manufactured by Rowa Pharmaceuticals Ltd. in Ireland, whose active component is the substance Carbenoxolone Sodium. It is officially classified as a Topical Oral Anti-Ulcer Agent, belonging to the broader category of Antiulcer Agents, and is indexed under the WHO Anatomical Therapeutic Chemical (ATC) code A02BX01. Carbenoxolone is recognized for its role in supporting mucosal defense and integrity.

Composition, Origin, and Dosage Form

The core compound, Carbenoxolone, is chemically a synthetic derivative of glycyrrhetinic acid, which is a Triterpenoid compound naturally isolated from the licorice plant (Glycyrrhiza glabra). This synthetic nature ensures a controlled, purified compound for consistent therapeutic results. The specific preparation known as Rowagel is exclusively formulated as a 2% Gel, which defines its topical route of administration for direct surface application. The gel's composition is designed to form an adherent film, maximizing contact time with the superficial tissue breakdown, such as mouth ulcers, distinguishing it from oral Carbenoxolone forms.

General Purpose: Supporting Tissue Integrity

The general purpose of the Rowagel gel is to support the body’s natural process of repair and protection for superficial tissue damage. The preparation achieves this by promoting the integrity of the mucosal barrier against localized irritants, such as digestive enzymes or acid, while also providing a localized anti-inflammatory action. The medicine actively assists the body in recovering from localized lesions of the oral surface.

What side effects are possible with Rowagel?

Possible Side Effects and Safety Information

The safety profile for Rowagel, a topical oral gel containing Carbenoxolone Sodium, is based on government regulatory documentation that details the officially known adverse reactions and necessary safety restrictions.

Adverse Reaction Scope

Category Regulatory Documentation Statement
Adverse Reactions Side effects directly related to the active substance have not been reported for the topical gel formulation.
System-Organ Classes Potential localized reactions fall under Immune system disorders or Skin and subcutaneous tissue disorders.
Frequency Adverse events lack a formal frequency classification; often cited as Not Reported or Frequency Not Known.
Local Reactions Allergic reactions (possibly delayed) may occur due to certain excipients (non-active ingredients) within the gel formulation.

Safety-Related Restrictions and Contraindications

The drug's safety profile is significantly defined by constraints related to the potential systemic effects of Carbenoxolone, should absorption occur. These are listed as contraindications in the official prescribing information:

  • Severe Organ Impairment: The gel is contraindicated in patients with severe cardiac, renal, or hepatic impairment.
  • Cardiovascular Conditions: Use is contraindicated in patients who have hypertension (high blood pressure).
  • Low Albumin Levels: It is contraindicated in patients with a low level of serum albumin.
  • Concomitant Medication: It is contraindicated for patients who are currently receiving cardiac glycosides (heart medication).

Population-Specific Constraints

Official regulatory documents specify limitations for certain patient groups:

  • Elderly: Use is contraindicated in elderly patients.
  • Pregnancy and Lactation: The gel is contraindicated for use during pregnancy and lactation.
  • Pediatrics: Use is not recommended for children under 3 years of age.

Regulatory Safety Summary

The official safety structure emphasizes that the risk understanding is shaped by these administration-agnostic restrictions—which pertain to the active ingredient's known systemic risks—and not by frequently observed adverse reactions from the topical application itself. This framework ensures the safety limitations are clearly communicated, particularly for vulnerable populations and those with pre-existing conditions.

Overdose and Emergency Response

The overdose profile for Rowagel is based on the potential for excessive systemic absorption of Carbenoxolone Sodium. Overexposure is officially documented to lead to symptoms associated with serious electrolyte imbalance, specifically hypokalemia (low blood potassium) and significant sodium and fluid retention.

Documented overdose presentations include physiological signs such as marked hypertension (elevated blood pressure) and noticeable edema (swelling). Manifestations of severe hypokalemia, such as pronounced muscle weakness and cramps, are also described in regulatory documents. Severe overexposure carries the risk of escalating to serious, life-threatening outcomes, including dangerous cardiac arrhythmias.

Immediate medical attention is required if any severe or persistent symptoms are present, or if signs of a life-threatening allergic reaction occur. Patients must seek help immediately for symptoms such as chest pain, severe trouble breathing, or signs of collapse.

Official management guidance specifies that no specific antidote is known for Carbenoxolone Sodium overdose. Treatment consists of immediate symptomatic and supportive treatment, which includes correcting electrolyte abnormalities and continuous monitoring of vital signs. Overdose risks are noted as potentially more severe for the elderly and individuals with pre-existing cardiac or renal conditions.

Therapeutic Uses of Rowagel

Based on the product's established therapeutic profile for topical use, this agent is commonly used for symptomatic relief and supportive symptomatic management of lesions. The primary indications include mouth ulcers (aphthous ulcers), lip sores, and minor stomatitis. This application is relevant across domains where short-term symptomatic assistance is appropriate.


Primary Therapeutic Focus

Rowagel is primarily applied in addressing situations involving symptoms related to inflammatory or irritative states resulting from superficial tissue breakdown. The medication helps improve day-to-day comfort during symptomatic periods by easing the localized pain and soreness of these lesions. It contributes to easing the overall symptom load by supporting the recovery of the affected tissue during recurrent or episodic manifestations, such as cold sores (Herpes labialis).

“A benefit of this topical agent is offering localized support that assists with maintaining functional stability when symptoms interfere with routine activities.”

Quick Fact: Relief for Localized Pain

The medication may be part of symptomatic management in conditions where symptoms become more noticeable, offering supportive relief during difficult episodes by easing distress and mitigating the functional strain associated with acute mucosal discomfort.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rowagel — Official Regulatory Information

The official eligibility profile for Rowagel (Carbenoxolone Sodium 2% Gel) is defined by strict prohibitions in government regulatory documentation, primarily establishing who must not use the medicine.


Category Official Regulatory Statement
Populations for whom use is allowed Adults and children over 3 years old are permitted to use the medicine under labeled conditions.
Populations for whom use is contraindicated Elderly patients (absolute contraindication).
Patients with severe cardiac, renal, or hepatic impairment.
Age-related eligibility rules Contraindicated in children under 3 years of age and in elderly patients.
Condition-specific eligibility rules Contraindicated in patients with hypertension (high blood pressure) or low serum albumin.
Pregnancy and lactation eligibility status Contraindicated during pregnancy and lactation (breastfeeding).
Eligibility-related restrictions Contraindicated in patients who are receiving cardiac glycosides (e.g., Digitalis).

Connection to the overall eligibility profile:

Official regulatory documents define the eligibility profile for this topical gel primarily through a set of absolute contraindications. These rules establish that use is permitted only for adults and children over 3 years old, while strictly prohibiting use in elderly patients and any individual with specific pre-existing systemic conditions such as severe cardiac or kidney failure, hypertension, or low serum albumin.

What should I know about interactions with other medicines?

The official interaction profile for Rowagel (Carbenoxolone Sodium) is defined by the potential for its active component to affect fluid and electrolyte balance in the body, which necessitates specific use restrictions documented in regulatory labeling.

Interaction-Related Restrictions

Co-administration with medication for a heart condition is strictly prohibited according to official regulatory documentation. This restriction is based on the risk of increased toxicity for certain heart medications, such as Digitalis Glycosides, which can be exacerbated by the drug's potential to induce low potassium levels (hypokalemia).

Pharmacodynamic Interaction Patterns

The medicine exhibits documented pharmacodynamic interactions with specific drug classes. Co-administration with Potassium-Depleting Diuretics (e.g., Thiazides) poses an additive risk for developing hypokalemia. Conversely, the co-administration of Rowagel with Potassium-Sparing Diuretics (e.g., Spironolactone or Amiloride) results in an antagonistic interaction, reducing the therapeutic efficacy of the diuretic agent. Additive effects leading to enhanced fluid and sodium retention are also documented when combined with Corticoids/Steroids.

Population-Specific Constraints

Use is contraindicated in certain patient populations due to heightened interaction risk. This includes individuals who suffer from severe heart, liver, or kidney complaints and those with existing high blood pressure. These constraints stem from the increased susceptibility to complications from potential systemic electrolyte and fluid imbalances.

Mechanism of Action

Rowagel: Mechanism of Action Summary

Modulating Local Glucocorticoid Activity via 11beta -HSD2 Inhibition

Rowagel's primary action is the inhibition of the enzyme 11beta -Hydroxysteroid Dehydrogenase Type 2. This molecular blockade prevents the inactivation of the body's natural anti-inflammatory hormone, cortisol, leading to an elevated concentration of active cortisol exclusively at the application site. This mechanism initiates a localized anti-inflammatory cascade and modulates signaling within the tissue.

Reinforcing Mucosal Cytoprotection Pathways

A secondary domain involves the modulation of pathways related to mucosal integrity. The drug acts by inhibiting the degradation of protective mediators, specifically Prostaglandin E2 ( PGE2), thereby sustaining their levels. This biochemical action stimulates the increased secretion of mucus and bicarbonate, reinforcing the tissue's physical and chemical barrier against localized irritants.

Contextual Constraints and Systemic Specificity

The overall physiological effect arises from the complementary action of localized inflammation suppression and physical barrier reinforcement. While the molecule interacts with several targets, including Gap Junctions, its functional contribution is primarily driven by the local modulation of cortisol and the enhancement of cytoprotection, restricting its effects mainly to the peripheral application site.

Dosage and Administration Information

Administration Guidelines for Rowagel

Rowagel (carbenoxolone sodium 2% gel) is intended solely for topical use and must be applied directly to the affected areas, such as lesions, sores, or blisters, in the mouth or on the lips.

Administration Scope and Dosing

The required frequency is four times daily. To ensure the gel remains on the affected site for a sufficient duration, application should be specifically timed after meals and at bedtime.

Administration Detail Guideline
Route of Administration Topical use (on lesions/sores)
Frequency Four times daily
Timing After meals and at bedtime
Age Restriction Adults and children over 3 years of age
Procedural Condition The gel must be applied quickly and allowed to remain on the affected area as long as possible

Procedural Sequence

The following steps constitute the administration procedure for Rowagel:

  1. Apply the gel quickly to the lesions, sores, or blisters.
  2. The application must be performed four times per day.
  3. Ensure the application occurs after meals and again at bedtime.
  4. Maximize the retention time by allowing the gel to remain on the affected area for the longest possible duration.

If a dose is missed, apply the gel as soon as remembered and then continue with the regular schedule. Treatment should be reviewed by a healthcare professional if the lesions fail to heal within three weeks.

Recent Clinical Evidence

Research evidence / Overview of Studies for Rowagel

Evidence for Use in Mouth Ulcers (Aphthous Stomatitis)

This section will summarize the types of research, primarily small-scale randomized controlled trials and systematic reviews, that have investigated the topical use of Carbenoxolone sodium for acute mouth ulcers, focusing on what outcomes, such as healing time and pain scores, were examined in these studies.

Research has examined the topical use of Carbenoxolone sodium in conditions characterized by fluctuating or episodic manifestations, specifically focusing on oral ulcers. Studies monitored patient-reported outcomes describing perceived discomfort and outcomes related to physical discomfort, such as the size of the ulcer and the time until the lesion begins to heal. This research contributes to the record of what has been observed so far in patients experiencing these acute or disruptive episodes.

In these studies, findings indicate patterns related to how symptoms evolved in the observed populations. Research has explored whether the topical agent was associated with patterns related to healing or changes in the reported severity of pain in some study settings. However, evidence quality varies across studies, and some of the data are older.

Evidence for Use in Herpetic Lesions (Lip Sores)

This part will describe the clinical evidence base for the use of the topical agent in managing herpetic lesions, including the nature of studies (such as case reports and observational studies) and the specific measurements of episode duration and discomfort that researchers assessed.

Topical Carbenoxolone was evaluated in studies focusing on episodes where symptoms become more noticeable, specifically for conditions associated with acute or disruptive episodes like cold sores (herpetic lesions) on the lips. Studies conducted during periods of increased symptom activity report how symptoms evolved in the observed populations. Earlier reports documented observations related to changes in healing time and pain scores during the observation period. Findings from this research provide insight into short-term changes monitored over defined time intervals.

However, comparative evidence is lacking, and some trials exploring short-term symptom changes yielded mixed findings regarding the outcomes when the agent was compared against other compounds studied. Research provides context but not individual predictions, and sample sizes for these types of studies were also modest.

What is Still Uncertain About the Research Evidence

The evidence quality varies across studies, with many trials being older or having small sample sizes, contributing to low certainty regarding specific research questions. Furthermore, there are significant research limitation frames, as comparative evidence is lacking against many treatments, and data for certain groups remain insufficient. The evidence highlights what is known—and what is still uncertain—about the overall research base for the topical gel.

Key Studies & References

  1. Topical carbenoxolone sodium in the management of herpes simplex infection
  2. Carbosan 2% w/w Gel - HPRA Product Information Leaflet (Supporting indication, dosage, and special populations context)

Frequently Asked Questions (FAQ)

Common questions about Rowagel (FAQ)

Q: How quickly does Rowagel start to work?

A: Official guidelines focus on maximizing the contact time of the gel with the lesion by applying the product four times daily. This schedule is required to maintain the localized effect of the drug. Specific information on the exact time until the initial feeling of relief is generally not defined in the regulatory documents.

Q: How long do the effects of Rowagel last?

A: The frequency defined in official use instructions is an indication of the expected duration of the localized effect. Regulatory guidance specifies application four times daily—after meals and at bedtime—to ensure the affected area is continuously treated with the active ingredient.

Q: Does Rowagel go into the bloodstream?

A: The mechanism of action is described in official documents as being primarily local, with the aim of restricting effects to the application site. However, the active component is known to potentially influence fluid and electrolyte balance if absorbed systemically, which is the basis for usage constraints in patients with severe heart or kidney conditions.

Q: Can Rowagel be used on large areas of the body?

A: Rowagel is indicated for topical use on specific localized lesions, such as ulcers in the mouth or on the lips. Regulatory constraints suggest the product is not intended for application over large areas of the body, which helps maintain the localized effect and minimize the risk of increased systemic exposure.

Q: Are there specific areas of the body where Rowagel should not be applied?

A: Official administration guidance specifies application only to lesions, sores, or blisters in the mouth or on the lips. Official product safety guidance indicates that contact with the eyes should be avoided, as is general application to healthy skin outside the lesion area, since the product is a local treatment.

Q: What types of allergic reactions are possible with Rowagel?

A: Regulatory documents indicate that the active ingredient, Carbenoxolone sodium, and certain non-active components in the gel may cause local skin reactions, including irritation or the possibility of delayed allergic reactions (hypersensitivity). A healthcare professional should be contacted if irritation or a rash occurs.

Q: Is Rowagel used for acute injuries or long-term conditions?

A: Regulatory guidance suggests that if the lesions being treated fail to heal within three weeks, the treatment should be reviewed by a healthcare professional. This time frame frames the use of the drug as treatment for acute or short-term mucosal conditions.

Q: Is there a limit on how long a person can use Rowagel?

A: Official guidelines state that continuous self-treatment should be reviewed by a healthcare professional if the lesions do not heal within three weeks. This establishes a recommended maximum duration for continuous use without re-evaluation.

Q: Why is hand washing required after applying Rowagel?

A: Hand washing is a standard practice for topical medications. It is recommended to minimize the risk of transferring the active drug to other sensitive areas of the body, such as the eyes, or accidentally ingesting any residual active ingredient.

Q: Does Rowagel interact with common over-the-counter pain medicines?

A: Official documentation lists specific interactions with drug classes that affect fluid and electrolyte balance, such as potassium-depleting diuretics. There is no specific official warning against the co-administration of Rowagel with common over-the-counter analgesics like acetaminophen or ibuprofen.

Q: Is Rowagel the same as other pain relief gels?

A: Rowagel is a topical gel containing Carbenoxolone sodium, which works by a unique mechanism involving localized enzyme inhibition and mucosal cytoprotection. This differs from many common over-the-counter pain relief gels, which often contain local anesthetics or other types of anti-inflammatory drugs.

Q: Why do people use Rowagel instead of taking a pill?

A: Rowagel is for topical use only on specific oral lesions, which results in a localized action, concentrating the anti-inflammatory and cytoprotective effects at the application site. This approach minimizes the systemic (whole-body) effects that an oral medication would typically have.

Q: What should I do if I accidentally swallow a small amount of Rowagel?

A: Since the medication is applied in the mouth, if a small amount is swallowed, the mouth can be rinsed with water. Official safety data sheets for the active ingredient state that induction of vomiting is not recommended, and medical advice should be sought for guidance on accidental ingestion.

Q: What is the main difference between Rowagel and a heating pad?

A: Rowagel is a medicinal product that uses an active pharmaceutical ingredient to produce a localized anti-inflammatory and tissue-protecting effect. A heating pad is a physical device that uses warmth to stimulate blood flow and provide comfort but does not contain a medicinal component.

Q: Is Rowagel available without a prescription?

A: Regulatory listings in various countries indicate that Rowagel is classified as a Prescription Drug (RX). This means the product requires authorization from a healthcare professional for dispensation.

Q: Does using more Rowagel make it work better?

A: The dosage is strictly defined in official guidelines as four times daily, which is the amount determined to be appropriate for the indicated use. Using more than the specified amount is not officially documented as increasing efficacy and may increase the potential for systemic exposure.

Q: What are the ingredients in Rowagel besides the active drug?

A: In addition to the active ingredient, Carbenoxolone Sodium, the gel contains several excipients. These include a basis for the gel, polyoxyethylene 30 cetylstearyl alcohol, and a lemon oil fragrance containing compounds like limonene.

Q: Are there any food or drink restrictions while using Rowagel?

A: Official instructions require the gel to be applied after meals and at bedtime. This timing is a condition of use intended to ensure the gel remains on the lesion for the longest possible duration. Eating or drinking immediately after application would likely remove the gel and reduce its contact time.

Q: Does Rowagel have a strong smell?

A: The official physical description in regulatory documents states that the gel is a translucent, colorless gel with a lemon odor. This is due to the inclusion of a lemon oil fragrance.

Q: Is it okay to shower shortly after applying Rowagel?

A: Since Rowagel is intended for topical use in the mouth and on the lips, showering does not directly affect the application site. However, the application should always be timed as directed (after meals and at bedtime) to maximize the retention time of the gel on the lesion.

Q: What does the research say about Rowagel for specific joint pain?

A: Rowagel is officially indicated for the symptomatic relief and treatment of mouth ulcers, lip sores, and aphthous changes in the oral mucous membranes. There is no official regulatory information supporting its use for joint pain, which is considered an unapproved use.

Q: Are there any warnings about Rowagel and stomach issues?

A: Unlike some other pain relievers, Rowagel's mechanism of action is noted to include the enhancement of mucosal cytoprotection pathways. This relates to the protection of internal linings, and the gel formulation is intended for local use, which limits systemic exposure to the digestive tract.

Q: Is Rowagel safe for older adults (seniors)?

A: The drug is contraindicated in patients with severe cardiac or renal failure. Its use in older adults requires caution due to the risk of side effects like fluid retention and electrolyte imbalances. Close monitoring by a healthcare professional is considered necessary for this population group.

Q: Can Rowagel be applied on broken skin?

A: The product is indicated for use on lesions and ulcers (which involves broken mucous membranes) in the mouth and on the lips. It is not intended for general application on other areas of broken skin outside the indicated sites, as this could increase the risk of systemic absorption.

Q: What is the proper way to store Rowagel?

A: Official packaging information states that Rowagel should be stored at temperatures not exceeding 25 C. It is important that the cap be replaced tightly after use to maintain product integrity and stability.

Q: Does Rowagel contain alcohol?

A: The official excipient list includes polyoxyethylene 30 cetylstearyl alcohol, which is used as an emulsifier in the gel. The list does not include ethanol (drinking alcohol).

Q: Does Rowagel affect driving or operating machinery?

A: Regulatory documents generally state that the use of the gel is unlikely to result in any impairment of the ability to drive or operate machinery. This is consistent with its topical route of administration and localized action.

Q: Does Rowagel work for headaches when applied to the neck?

A: The official regulatory indication is strictly for lesions in the mouth and on the lips. There is no official indication or evidence to support the use of the gel on the neck or for the treatment of headaches.

Q: Can I apply moisturizer or lotion after using Rowagel?

A: Official instructions emphasize allowing the gel to remain on the affected area as long as possible to maximize contact time. Applying another product, such as a moisturizer or lotion, immediately afterward would likely disrupt the gel layer and may reduce the intended localized effect.

Q: What is the role of the gel formulation in how the drug is absorbed?

A: The gel formulation is designed to be highly viscous, allowing it to adhere to the oral mucosal surface. This adherence is essential for achieving the necessary prolonged contact time to facilitate the localized action and controlled absorption of the active ingredient at the site of the lesion.

Q: Can Rowagel be used for swelling?

A: The product’s mechanism of action includes a local anti-inflammatory effect due to the localized elevation of cortisol. Swelling is a component of the inflammatory process, so the drug’s properties may help reduce localized swelling associated with the indicated oral lesions.

Q: Is it normal to feel mild burning when using Rowagel for the first time?

A: The product contains ingredients that are known to sometimes cause local skin irritation. While a mild sensation may occur, severe or persistent burning or irritation should prompt contact with a healthcare professional, as the active substance is classified as a skin irritant.

How should Rowagel be stored and disposed of?

Storage and Disposal Requirements

Rowagel (Carbenoxolone Sodium 2% Gel) must be stored under specific conditions mandated by official regulatory documents to maintain its quality and stability.

Storage Requirement Rule
Temperature Store at a temperature not exceeding 25°C.
Container Integrity The cap on the tube must be replaced tightly after use.
Child Safety Keep this medicine out of the sight and reach of children.
Disposal Rule Do not throw away via wastewater or household waste.

Disposal of unused or expired Rowagel must follow regulatory guidelines. To ensure environmental protection, official instructions advise consulting a pharmacist for guidance on how to properly discard any medicines that are no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rowagel found in:

A-Z Index: